Triple-Drug attack aims to wipe out mantle cell lymphoma
NCT ID NCT03872180
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether combining three drugs—bendamustine, obinutuzumab, and venetoclax—can improve outcomes for people with untreated mantle cell lymphoma. Bendamustine and venetoclax are chemotherapy drugs that kill or stop cancer cells from growing, while obinutuzumab is an immunotherapy that helps the immune system attack the cancer. The study enrolls about 23 participants and measures how many achieve a complete response (no detectable cancer) after initial treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bendamustine, obinutuzumab, and venetoclax
What this could lead to
If successful, this combination could become a more effective first-line treatment for mantle cell lymphoma, potentially leading to deeper remissions and longer disease control.
What could go wrong
This is a small, early-phase trial (23 participants) without a comparison group, so results may not apply broadly. The drug combination can cause significant side effects, including low blood counts and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Johns Creek Hospital
Johns Creek, Georgia, 30097, United States
-
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States